GREENWICH, Conn.--(BUSINESS WIRE)--Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 11,986,473 titled, “Prevention and/or Treatment of Contrast-Induced Acute Kidney Injury” for its Phase 3-ready product, ST-62516 (trimetazidine), a cardiorenal metabolic modulator. The patent provides exclusivity through 2037, with broad claims for the reduction of Acute Kidney Injury (AKI) and Major Adverse Cardiac and Kidney Events (MACKE) in patients undergoing procedures with contrast dyes.
Saghmos is developing ST-62516 to reduce the risk of AKI and MACKE after contrast procedures such as percutaneous coronary intervention (PCI). The interrelationship between cardiovascular disease, kidney disease, and metabolic disease has recently been termed CKM Syndrome. Patients with this syndrome are at increased risk of adverse cardiovascular and kidney outcomes after contrast procedures such as PCI. ST-62516 is uniquely positioned to address this unmet need.
"We are excited about the continued growth of Saghmos’ intellectual property estate, which now has two issued U.S. patents as well as an issued patent in Japan,” commented Anna Kazanchyan, MD, Founder and CEO of Saghmos Therapeutics.
According to the American Heart Association, one in three US adults have three or more risk factors for CKM. Over one million PCI procedures are performed annually in the US and about half of these individuals have CKM Syndrome, or are aged 75 and older. CKM Syndrome in combination with certain procedure-related factors, adversely affects the safety of PCI and increase the risk of AKI and MACKE. This is a major unmet medical need with no FDA-approved drugs available. ST-62516 could benefit all people undergoing a PCI, not just those with CKM Syndrome, by reducing the threat of AKI and MACKE after PCI.
About Saghmos Therapeutics
Saghmos Therapeutics is developing ST-62516 (trimetazidine) to reduce the risk of Acute Kidney Injury (AKI) and Major Adverse Cardiac and Kidney Events (MACKE) after contrast procedures such as percutaneous coronary intervention (PCI). ST-62516 is poised to enter a Phase 3 study. The company recently announced a collaboration with the Duke Clinical Research Institute (DCRI) to optimize all aspects of and plan the operationalization of the Phase 3 study.
Forward looking statements
This press release contains forward-looking statements, pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Saghmos Therapeutics’ business, intellectual property, clinical and regulatory plans, commercial potential, and the value and benefits of ST-62516. In any forward-looking statement in which Saghmos expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Saghmos’ actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources, uncertainties and changes related to the law and regulatory process, and general changes in the economic environment. These forward-looking statements are based on our current expectations. Saghmos does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.
